Clinical Report: Could GLP-1s Curb Violence?

Overview

Research indicates that GLP-1 receptor agonists may reduce the association between impulsivity and violent behavior. Current users of GLP-1 medications showed a 62% attenuation in the link between impulsivity and violence compared to former users, according to a study from Rutgers University.

Background

GLP-1 receptor agonists are primarily known for their role in managing metabolic conditions. Emerging studies suggest they may also influence behavioral outcomes, particularly in populations with high impulsivity and alcohol use.

Data Highlights

Key Findings

• Current GLP-1 users showed a 62% reduction in the association between impulsivity and violent behavior.
• Alcohol use was also linked to violent behavior, but findings were less consistent among GLP-1 users.
• GLP-1 use was not independently associated with lower violence rates, according to the study.
• The study was cross-sectional and cannot establish causality.
• Impulsivity and alcohol use were strongly associated with self-reported violent behavior.

Clinical Implications

Clinicians should consider the potential behavioral effects of GLP-1 receptor agonists in patients with impulsivity and alcohol use issues. Further research is needed to explore the mechanisms by which these medications may influence violent behavior.

Conclusion

The findings indicate that the association between impulsivity and violence was attenuated among current GLP-1 users, warranting further investigation into their behavioral effects.

Related Resources & Content

1. Conexiant, Criminology Jet Lag Loves a Bad Itinerary, 2026 -- Can use of popular weight loss medications reduce behaviors linked to violent crime?
2. Conexiant, GLP-1 Drugs Tied to Lower Addiction Risk, 2026 -- GLP-1 Drugs Tied to Lower Addiction Risk
3. Conexiant, FDA Drops Warning From GLP-1 RAs, 2026 -- FDA Drops Warning From GLP-1 RAs
4. Conexiant, GLP-1 Drugs Linked to GI Effects, Uncertain Signals, 2026 -- GLP-1 Drugs Linked to GI Effects, Uncertain Signals
5. American Diabetes Association, The American Diabetes Association Releases “Standards of Care in Diabetes—2026”, 2026 -- The American Diabetes Association Releases “Standards of Care in Diabetes—2026”
6. JAMA Network, Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial, 2026 -- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
7. Stat News — I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
8. The American Diabetes Association Releases “Standards of Care in Diabetes—2026” | American Diabetes Association
9. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial | Trials | JAMA Psychiatry | JAMA Network
10. Can use of popular weight loss medications reduce behaviors linked to violent crime? | John Wiley & Sons, Inc.